IMV:CC News and Press, Imv Inc. From 06/22/22

IMV achieves predetermined milestone to access the remaining $US10 Million under its Debt Facility with Horizon Phase 2b AVALON trial in platinum-resistant ovarian cancer open for enrollment IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a ...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating...

Positive clinical results in bladder cancer were presented at the AACR annual meeting, including 2 confirmed complete responses (CRs) and 3 partial responses (PRs) per RECIST v1.1; CRs and PRs were observed in patients previously treated with checkpoint inhibitors; Tre...

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference cal...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company’s lead compound, maveropepimut-S (MVP-S), will be showcased in...

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that its Board of Directors has el...

Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy The combination treatment was well-tolerated with adverse events...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company will present a poster at IMMUNOLOGY™ 2022, the annual meeting ...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in the 21 ...

First patient dosed in VITALIZE Phase 2B trial in relapsed/refractory DLBCL Metastatic bladder cancer cohort data from Phase 2 basket trial to be presented at late-breaking symposium at AACR Phase 2B Avalon trial in advanced ovarian cancer to start in second ...